Douglas Levine MD retweeted
The Supreme Court decision in Dobbs v. Jackson is a destructive setback for ob-gyns and patients. However, we’ll continue with unwavering resolve to support all people who struggle against interference with the patient–physician relationship.
Douglas Levine MD retweeted
This is awesome!
A more perfect union.
Douglas Levine MD retweeted
Women w/BRCA1 mutation age 35 – 50 with increased risk 4 ovarian cancer may enroll in the SOROCk study looking at whether removal of fallopian tubes alone can lower ovarian cancer risk nearly as much as removing both the ovaries and fallopian tubes. ow.ly/rUHw50HuyQB
Douglas Levine MD retweeted
Welcome to Book Chapter Club.
The first rule of Book Chapter Club is: you do not agree to write book chapters. The second rule of Book Chapter Club is: you DO NOT agree to write book chapters.
Douglas Levine MD retweeted
COVID‐19 outcomes of patients with gynecologic cancer in New York City acsjournals.onlinelibrary.wi…
Douglas Levine MD retweeted
FDA approves niraparib for first-line maintenance of advanced ovarian cancer fda.gov/drugs/drug-approvals… Progress for women with #ovary cancer! @SGO_org #gyncsm @SHAREing
Douglas Levine MD retweeted
Impressive activity- 40% RR for Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial - The Lancet Oncology thelancet.com/journals/lanon…
Douglas Levine MD retweeted
Thanks to @rymarwil, @levinemd and @TinasWish for making it happen! A great engineering-medicine collaboration! Continued by @zviyaari! Great to present at @AACR #AAC19
#OvarianCancer is difficult to treat at an advanced stage, when it is typically diagnosed. @HellerLab has developed a small implantable sensor that shows promise for detecting an early warning sign for this cancer. #AACR19 #Nanosensors https://teapawt.org/t.co/QFwFGXqgtK
Douglas Levine MD retweeted
Congratulations to the SGO past presidents at opening session of the 50th annual meeting of the Society of Gynecologic Oncology!
Douglas Levine MD retweeted
Science Update: TW researchers @levinemd of @nyulangone and @HellerLab of @sloan_kettering are at the forefront of research using biomarkers and nanotechnology to detect #OvarianCancer at its earliest stages. #TinasWishIsMyWish
Douglas Levine MD retweeted
Congrats Dr. Jessica Lee! Refer high risk #emca patients for #genetic testing despite intact #MMR IHC @ASCO2018 @nyulangone
Douglas Levine MD retweeted
if ONLY we had a vaccine against HPV...... oh, wait..... if ONLY we could implement a vaccination program that works and gets the vaccine to the people that need it most..... here's looking at you, Australia #rolemodel teapawt.org/theNCI/status/98259133…
The combination of #HPV vaccination and cervical screening can provide the greatest protection against #cervicalcancer: cancer.gov/about-cancer/caus…
Douglas Levine MD retweeted
Don’t underestimate a good laugh at work @Oslounivsykehus teapawt.org/naturenews/status/9794… – at Miami Beach, FL
Humour in the workplace is linked with strong employee performance, effective stress-coping mechanisms and sturdy group cohesiveness. go.nature.com/2pNCJVO
Douglas Levine MD retweeted
2 insightful papers on origins of #ovariancancer nature.com/articles/s41467-0… @ronny_drapkin and nature.com/articles/s41467-0… @levinemd
Douglas Levine MD retweeted
Phase 2 of the cBioPortal architectural upgrade is now complete: The query interface has a fresh look and faster performance.
Douglas Levine MD retweeted
FDA approves immunotherapy for MSI-H or MMR deficient tumors. Progress for #emca Pts! sitcancer.org/aboutsitc/pres… @gyncsm @SHAREing
Douglas Levine MD retweeted
Niraparib maintenence in plat sens recurrent ov ca-improved PFS in all pts regardless of gBRCA mutation or HRD!! ca nejm.org/doi/full/10.1056/NE…






























